Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VLX 1005

Drug Profile

VLX 1005

Alternative Names: ML-355; VLX-1005

Latest Information Update: 09 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eastern Virginia Medical School; National Institutes of Health (USA); Thomas Jefferson University; University of California
  • Developer University of Michigan; Veralox Therapeutics
  • Class Amines; Antihyperglycaemics; Antithrombotics; Benzothiazoles; Small molecules; Sulfonamides
  • Mechanism of Action 12-lipoxygenase inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Heparin-induced thrombocytopenia and thrombosis syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heparin-induced thrombocytopenia and thrombosis syndrome
  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 26 Sep 2023 Phase-II clinical trials in Heparin-induced thrombocytopenia and thrombosis syndrome (In adults) in USA (IV) (NCT05785819)
  • 15 Jun 2023 Pharmacodynamics data from preclinical studies in Type I diabetes mellitus presented at the 105th Annual Meeting of the Endocrine Society (ENDO-2023)
  • 13 Jun 2022 Adverse events data from a phase Ia trial in healthy volunteers released by Veralox Therepeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top